Management of Multiple Myeloma Patients Meeting CRAB Criteria

Diagnostic Confirmation

• The International Myeloma Society recommends confirming the diagnosis with ≥10% clonal plasma cells on bone marrow examination or a biopsy-proven plasmacytoma 1, 4
• The European Society for Medical Oncology suggests evidence of end-organ damage (CRAB criteria), including hypercalcemia, renal insufficiency, anemia, and bone lesions, to confirm the diagnosis 1, 4

Treatment Algorithm Based on Age and Transplant Eligibility

• The National Comprehensive Cancer Network recommends bortezomib, melphalan, prednisone (VMP) for approximately 8-12 cycles in elderly patients (≥65 years or not eligible for transplant) 1, 6
• The National Comprehensive Cancer Network suggests melphalan, prednisone, thalidomide (MPT) as an alternative treatment option for elderly patients (≥65 years or not eligible for transplant) 1, 6

Special Considerations

• The National Comprehensive Cancer Network recommends bortezomib-based regimens for patients with renal impairment, as they can be safely administered without dose adjustment 3
• The European Society for Medical Oncology suggests avoiding NSAIDs and maintaining adequate hydration in patients with renal impairment 4
• The International Myeloma Society recommends aggressive hydration with normal saline and bisphosphonates (zoledronic acid or pamidronate) for patients with hypercalcemia 4, 5
• The European Society for Medical Oncology suggests bisphosphonates (zoledronic acid or pamidronate) to reduce skeletal-related events in patients with bone disease 4

Common Pitfalls to Avoid

• The National Comprehensive Cancer Network recommends immediate intervention in patients with clear CRAB criteria, as delaying treatment can lead to increased morbidity and mortality 1, 3
• The European Society for Medical Oncology suggests distinguishing between smoldering multiple myeloma and symptomatic multiple myeloma to avoid confusion and ensure appropriate treatment 3, 4